Figure 4
Figure 4. Monocytes from NOD-SCID mice engrafted with human AML express increased YM-1. (A) NOD-SCID mice were injected with AML cells from patients. After engraftment, bone marrow was harvested from the femurs, and the expression of YM-1 on murine monocytes (Ly6C+) was assessed by flow cytometry. (B) Increased percentage of YM-1 positive monocytes in NOD-SCID mice engrafted with human AML. NOD-SCID mice were injected with AML cells from patients. After engraftment, bone marrow was harvested from the femurs, and the percentage of YM-1+ Ly6C+ murine monocytes was assessed by flow cytometry (***P = .0001).

Monocytes from NOD-SCID mice engrafted with human AML express increased YM-1. (A) NOD-SCID mice were injected with AML cells from patients. After engraftment, bone marrow was harvested from the femurs, and the expression of YM-1 on murine monocytes (Ly6C+) was assessed by flow cytometry. (B) Increased percentage of YM-1 positive monocytes in NOD-SCID mice engrafted with human AML. NOD-SCID mice were injected with AML cells from patients. After engraftment, bone marrow was harvested from the femurs, and the percentage of YM-1+ Ly6C+ murine monocytes was assessed by flow cytometry (***P = .0001).

Close Modal

or Create an Account

Close Modal
Close Modal